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with MCV (16.7% vs 38.6% vs 26.3%; p¼0.042), mainly due to a higher
need for permanent pacemakers (6.3% vs 24.6% vs 10.5%; p¼0.019).
After multivariate analysis MCV remained predictor of VARC com-
bined early safety endpoints.General
n[162ACCURATE
n[48CoreValve
n[57SAPIEN XT
n[57 pAge (y) 82.636.55 82.295.33 82.397.72 83.146.32 0.75
Male (n) 45.7% (74) 45.8% (22) 45.6% (26) 45.6% (26) 1BMI (Kg/m2) 26.964.33 28.393.93 25.604.13 27.114.49 0.001
Hypertension (n) 83.1% (133) 85.4% (41) 76.8% (43) 87.5% (49) 0.28Diabetes (n) 34.4% (55) 33.3% (16) 32.1% (18) 37.5% (21) 0.823COPD (n) 11.9% (19) 21.3% (10) 7.1% (4) 8.9% (5) 0.073Coronary Artery
Disease > 50% (n)51.9% (83) 47.9% (23) 53.6% (30) 53.6% (30) 0.806Creattinine
Clearance < 60mL/
min (n)71.7% (114) 68.8% (33) 81.8% (45) 64.3% (36) 0.105NYHA Functional Class
III/IV (n)74.7% (118) 89.6% (43) 69.6% (39) 66.7% (36) 0.016EUROSCORE II 7.596.42 6.534.5 8.296.66 7.857.49 0.41
STS PROM 6.033.7 6.072.81 5.453.08 6.634.82 0.441
Left Ventricle Ejection
Fraction (%)57.4113.15 58.6610.79 57.0214.4 56.7213.8 0.998Mean Aortic Valve
Gradient (mmHg)52.8414.92 50.9113.01 53.2615.90 54.0415.50 0.575Aortic Valve Area
(cm2)0.690.15 0.730.16 0.670.14 0.670.14 0.105CONCLUSIONS Although the three devices have shown good device
success rates and hemodynamic improvement on echocardiogram,
CoreValve use lead to higher combined early safety endpoints, mainly
because of more permanent pacemaker usage. Larger cohorts or ran-
domized trials are needed do corroborate these ﬁndings.
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BACKGROUND Increased aortic valve calciﬁcation has been shown to
be associated with perivalvular regurgitation (PVR) post TAVR.
Nonetheless, there is limited data on the impact of extremely low
aortic valve calciﬁcation on the acute success of balloon-expandable
TAVR.
METHODS We studied patients with severe aortic stenosis that un-
derwent balloon-expandable TAVR and had a pre-procedural non-
contrast CT. Patients that had an aortic valve calciﬁcation score
(AVCS) of less than 1500 Agatston units (AU) were compared to pa-
tients with higher calciﬁcation scores.
RESULTS Seventy-four patients had low AVCS compared to 489 with
higher AVCS (mean Agatston score: 1049305 vs. 39892020). Pa-
tients with mild aortic valve calciﬁcation were younger (80.38 vs.
82.98.1; p¼0.01), had higher body mass index (29.17.4 vs. 26.85.8;
p¼0.01) and had female predominance (70.3% vs. 32.1%; p<0.001),
compared to patients with higher calciﬁcation scores. Pre-TAVR, pa-
tients with aortic valve calciﬁcation score 1500 had lower mean
aortic valve pressure gradient and less stenotic aortic valves
(37.39.8mmHg vs. 46.813.4mmHG; p<0.001 and 0.670.13cm2 vs.
0.630.15cm2; p¼0.02). Device success was 100% in the low calciﬁ-
cation group compared to 95.9% in patients with higher AVCS
(p¼0.076). Postdilatation and 2nd valve implantation was done in
8.8% and 0% compared to 9.5% and 3.7%, respectively (p¼0.85 and
0.09). Postprocedural PVR in the mild aortic valve calciﬁcation group
was lower (mild or more PVR: 13.5% vs. 25.9%; p¼0.023).There was nocase of valve embolization in the mild AVCS group. Thirty-day mor-
tality and major complications were similar between groups (Table).
One year mortality was 13.2% vs. 16.4% in the AVCS1500 vs.
AVCS>1500, respectively (p¼0.61).
Table. Procedural details and 30-days clinical outcomeAVCS £ 1500 Agatston
units
(n[74)AVCS > 1500 Agatston
units
(n[489) p-valueProcedural details:Device success 74 (100) 469 (95.9) 0.072nd valve 0 (0) 18 (3.7) 0.09Postdilatation 7 (9.5) 43 (8.8) 0.85Perivalvular leak: 0.02None / trace 64 (86.5) 358 (74.1)Mild 10 (13.5) 111 (23)Moderate 0 (0) 13 (2.7)Severe 0 (0) 1 (0.2)Valve embolization 0 (0) 3 (0.6) 0.530-days outcome:Mortality 1 (1.4) 13 (2.1) 0.5CVA/TIA 1 (1.4) 14 (2.9) 0.45Major bleeding 3 (4.1) 19 (3.9) 0.94Major vascular 4 (5.4) 13 (2.7) 0.2New permanent
pacemaker3 (4.9) 40 (10.1) 0.2Values are n (%).
CONCLUSIONS Balloon-expandable TAVR can be performed safely in
patients with extremely low AVCS. We demonstrated excellent acute
procedural outcome, lower rates of postprocedural PVR and no case of
valve embolization.
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BACKGROUND In patients with severe aortic stenosis undergoing
transfemoral aortic valve implantation (TAVI) device success was
signiﬁcantly higher with the balloon-expandable Edwards XT valve
(EXT) compared with the self-expanding CoreValve (CV) in the ran-
domized CHOICE trial. The second generation Edwards Sapien 3 valve
was designed to reduce paravalvular aortic regurgitation. Absence of
post-procedural aortic regurgitation was associated with a lower acute
and long-term mortality in the Partner trial. We compared the
outcome of the ES3 with the CoreValve in patients undergoing TAVI.
METHODS The ﬁrst 100 consecutive patients treated with the ES3
were compared with the last 100 consecutive patients treated with the
CoreValve (Clinical Trial Registration: NCT02162069). Mean STS-Score
was 10.27.9%. Post-procedural aortic regurgitation, rate of perma-
nent pacemaker implantation, and device success were analyzed ac-
cording to VARC criteria. Device size was based on multislice
computer tomography performed with a 256 Philips Brilliance iCT
scanner. Measurements of aortic annulus, left ventricular outﬂow
tract (LVOT) were performed with a dedicated software (3mensio
Structural Heart, version 7.0).
RESULTS Baseline characteristics were mostly similar between the
CoreValve and ES3 population: age 816 vs. 826 years (p¼0.24),
female 49% vs. 52% (p¼0.67), diabetes mellitus 34% vs. 38% (p¼0.56),
coronary artery disease 61% vs. 60% (p¼0.89), history of cardiac
surgery 14% vs. 9% (p¼0.27), pulmonary disease 36% vs. 60%
(p<0.01). Also the computer tomography acquired parameters did not
differ signiﬁcantly between the EXT and ES3 population. Post dilation
was necessary in 11% after CoreValve implantation and in no patient
after ES3 implantation (p<0.01). Rate of device success according to
